Related Experiment Video

Updated: Aug 10, 2025

Experimental Model to Evaluate Resolution of Pneumonia
09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

1.4K

Lactate dehydrogenase and the severity of adenoviral pneumonia in children: A meta-analysis

Min Zou1, Yang Zhai2,3, Xiaoping Mei4

  • 1Department of Pediatrics, Guangxi International Zhuang Medicine Hospital, Nanning, China.

Frontiers in Pediatrics
|February 13, 2023
PubMed

Insights

High pretreatment lactate dehydrogenase (LDH) levels are linked to severe adenoviral pneumonia (ADVP) in children. Elevated LDH indicates increased risk of postinfectious bronchiolitis obliterans (PIBO) and mortality in these patients.

Area of Science:

  • Pediatric Pulmonology
  • Infectious Diseases
  • Biochemistry

Background:

  • Severe adenoviral pneumonia (ADVP) in children is associated with poor outcomes and high mortality rates.
  • Lactate dehydrogenase (LDH) is an enzyme released from damaged cells, potentially indicating disease severity.

Purpose of the Study:

  • To conduct a meta-analysis evaluating the association between pretreatment lactate dehydrogenase (LDH) levels and the severity, development of postinfectious bronchiolitis obliterans (PIBO), and mortality in children diagnosed with ADVP.

Main Methods:

  • A comprehensive literature search was conducted across multiple databases (PubMed, Embase, Web of Science, Wanfang, CNKI) up to August 3, 2022.
  • Relevant observational studies were identified and included in the meta-analysis.
  • A random effects model was employed to synthesize data and account for inter-study heterogeneity.

Main Results:

  • The meta-analysis included 23 studies involving 4,481 children with ADVP.
  • Children with severe ADVP exhibited significantly higher pretreatment LDH levels compared to those with non-severe ADVP (SMD: 0.51, 95% CI: 0.36 to 0.66).
  • Higher pretreatment LDH levels were also associated with the development of PIBO (SMD: 0.47, 95% CI: 0.09 to 0.84) and increased in-hospital mortality (OR: 3.10, 95% CI: 1.62 to 5.92) when LDH was >500 IU/L.

Conclusions:

  • Elevated pretreatment LDH levels in children with ADVP may serve as a significant indicator of disease severity.
  • High pretreatment LDH is associated with an increased risk of developing postinfectious bronchiolitis obliterans (PIBO).
  • Pretreatment LDH levels are a risk factor for increased mortality in children hospitalized with ADVP.
Abstract

Keywords:
adenoviral pneumonialactate dehydrogenasemeta-analysismortalitypostinfectious bronchiolitis obliteransseverity

More Related Videos

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

645
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics11:02

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

Published on: November 29, 2024

604

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
395
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
332
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
2.6K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
314
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
298
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
251